	US 12,344,899 B2
	Compositions and methods for therapeutics prescreening
Avi Schroeder, Binyamina (IL); and Zvi Yaari, Kiryat Ata (IL)
Assigned to TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, Haifa (IL)
Filed by TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, Haifa (IL)
Filed on Oct. 26, 2020, as Appl. No. 17/079,959.
Application 17/079,959 is a continuation of application No. 15/503,437, granted, now 10,815,530, previously published as PCT/IL2015/050826, filed on Aug. 13, 2015.
Claims priority of application No. 1414464 (GB), filed on Aug. 14, 2014.
Prior Publication US 2021/0040568 A1, Feb. 11, 2021
Int. Cl. A61P 43/00 (2006.01); A61K 49/00 (2006.01); C12Q 1/6886 (2018.01)

CPC C12Q 1/6886 (2013.01) [A61K 49/0004 (2013.01); A61K 49/0017 (2013.01); A61K 49/0084 (2013.01); C12Q 2600/136 (2013.01)]

20 Claims

1. A method of determining in vivo biodistribution of a type of carrier in a subject, the method comprising:

a. systemically administering to said subject a composition comprising a first type of carrier comprising one or more nucleic acid molecules comprising a barcode uniquely identifying said type of carrier;

b. obtaining from said subject a sample from a plurality of tissue comprising cells; and

c. identifying, in said cells the presence of said nucleic acid barcode, wherein the presence of said nucleic acid barcode indicates the in vivo biodistribution of said type of carrier to said tissue;

wherein each of said one or more nucleic acid molecules is 500 or fewer nucleotides in length;

thereby determining biodistribution of a type of carrier in a subject.